8-K: MetaVia's Vanoglipel Shows Positive Phase 2a MASH Data

MetaVia Inc. announced positive Phase 2a clinical trial data for vanoglipel (DA-1241) in treating metabolic dysfunction-associated steatohepatitis (MASH), demonstrating improvements in glucose control, liver health, and lipid profiles.

Summary

• Positive new data from the Phase 2a clinical trial of vanoglipel (DA-1241), a G protein-coupled receptor 119 (GPR119) agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) was announced.
• Vanoglipel demonstrated differentiated dual activity across both hepatic and metabolic pathways, leading to clinically meaningful improvements in glucose control, liver health, and plasma lipidomic profiles after 16 weeks of treatment.
• The data will be presented in a poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, taking place from November 7-11, in Washington D.C.
• The Phase 2a trial was a randomized, placebo-controlled study evaluating vanoglipel as monotherapy and in combination with a dipeptidyl peptidase-4 inhibitor (DPP4i) in 109 subjects with presumed MASH.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive Phase 2a clinical trial results for vanoglipel, demonstrating significant improvements across multiple key MASH and metabolic health indicators with excellent tolerability. This represents a major positive step in the drug's development.

Positives

• Vanoglipel demonstrated rapid and sustained improvements in glycemic control, with reductions in glycated hemoglobin (HbA1c) observed from the fourth week of treatment.
• At Week 16, mean HbA1c decreased by 0.54%p with vanoglipel monotherapy and 0.66%p with combination therapy, reflecting enhanced incretin action.
• Clinically meaningful HbA1c reductions of 0.37%p, 0.41%p, and 0.54%p were observed at weeks 4, 8, and 16, respectively, from a baseline of 6.99% (p < 0.05 vs. PBO), even with nearly half of participants being non-diabetic.
• The findings highlight vanoglipel's ability to improve glucose control independently of weight loss, suggesting a differentiated mechanism from other metabolic liver disease therapies.
• Vanoglipel significantly decreased plasma ALT levels in subjects with baseline ALT between 40 and 200 U/L, with monotherapy driving the majority of observed hepatoprotective effects.
• Liver steatosis improved as measured by controlled attenuation parameter (CAP), and liver stiffness reduced by vibration-controlled transient elastography (VCTE).
• Non-invasive assessments, including FAST and NIS-4 scores, also improved from baseline, reinforcing the potential to address both hepatic and metabolic components of MASH.
• Treatment reduced circulating biomarkers associated with cell death (CK18F/M30), inflammation (hs-CRP, CCL2), and fibrosis (TIMP1), consistent with its proposed hepatoprotective mechanism.
• Vanoglipel 100 mg reduced pathogenic lipids in plasma lipidomic profiles, including glycerolipids (DG36:4, TG52:4) and glycerophospholipids (PE38:4, PE38:5), suggesting favorable remodeling of lipid metabolism.
• Vanoglipel was well tolerated across all treatment groups, with no treatment-emergent adverse events leading to discontinuation, except for one in the placebo group.

Risks

• The company's ability to execute on its commercial strategy.
• Uncertainty regarding the sufficiency of existing cash on hand to fund operations.
• The timeline for regulatory submissions and obtaining regulatory approval for current and future product candidates.
• The ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results.
• Reliance on the cooperation of contract manufacturers, clinical study partners, and others involved in product development.
• Potential negative interactions between product candidates and any other products with which they are combined for treatment.
• The ability to initiate and complete clinical trials on a timely basis and recruit subjects for clinical trials.
• Whether clinical trial results will be consistent with the results of pre-clinical and previous clinical trials.
• Impact of costs related to the license agreement, including potential litigation or regulatory actions.
• The effects of changes in applicable laws or regulations.
• The effects of changes to the company's stock price on the terms of the license agreement and any future fundraising.
• Other risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

Future Outlook

The company plans continued development of vanoglipel as both a monotherapy and combination therapy for MASH and related metabolic disorders, supported by consistent biochemical, imaging, and metabolic improvements. MetaVia is also developing DA-1726 for the treatment of obesity.

Management Comments

• "The encouraging additional Phase 2a results, presented at AASLD, highlight vanoglipel's differentiated mechanism and its potential to target both hepatic and metabolic drivers of MASH in a single oral therapy." Hyung Heon Kim, President and Chief Executive Officer of MetaVia.
• "In addition to improvements in liver inflammation, fibrosis, and steatosis, vanoglipel demonstrated meaningful reductions in HbA1c among patients with type 2 diabetes and prediabetes, as well as favorable shifts in plasma lipidomic profiles, reducing disease-associated glycerolipids and glycerophospholipids linked to hepatic injury." Hyung Heon Kim, President and Chief Executive Officer of MetaVia.
• "These data reinforce vanoglipel's potential to address the complex interplay between metabolic dysfunction and liver disease." Hyung Heon Kim, President and Chief Executive Officer of MetaVia.
• "Following 16 weeks of treatment, vanoglipel showed consistent biochemical, imaging, and metabolic improvements, supporting its continued development as both a monotherapy and combination therapy for MASH and related metabolic disorders." Hyung Heon Kim, President and Chief Executive Officer of MetaVia.

Industry Context

Vanoglipel, as a GPR119 agonist, offers a differentiated mechanism by stimulating the release of key gut peptides GLP-1, GIP, and PYY, which play roles in glucose metabolism, lipid metabolism, and weight loss. Its ability to improve glucose control independently of weight loss distinguishes it from some other metabolic liver disease therapies. The MASH treatment landscape is highly competitive, with numerous therapies in development targeting various pathways. MetaVia's dual-activity approach could position vanoglipel favorably in addressing the complex interplay between metabolic dysfunction and liver disease.

Comparison to Industry Standards

• Vanoglipel's ability to improve glucose control independently of weight loss suggests its mechanism is differentiated from other metabolic liver disease therapies.
• MetaVia's other product candidate, DA-1726, a novel oxyntomodulin (OXM) analogue, demonstrated "best-in-class potential for weight loss, glucose control, and waist reduction" in a Phase 1 multiple ascending dose (MAD) trial for obesity, compared to selective GLP1R agonists.

Stakeholder Impact

• Shareholders: Positive clinical trial results could increase investor confidence and potentially lead to a higher stock price due to de-risking of the drug candidate.
• Patients with MASH/Type 2 Diabetes: Vanoglipel offers a promising new oral treatment option with a differentiated mechanism, potentially improving outcomes for a complex and underserved disease.
• Employees: Positive trial results validate research and development efforts, potentially boosting morale and job security within the company.
• Regulatory Authorities: Positive data supports progression towards further clinical trials and eventual regulatory approval, indicating potential for a new therapeutic option.

Next Steps

• Continued development of vanoglipel as both a monotherapy and combination therapy for MASH and related metabolic disorders.
• Presentation of detailed data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025 from November 7-11, 2025.

Key Dates

Recommendation

The Phase 2a results for vanoglipel are exceptionally strong, demonstrating clinically meaningful improvements across multiple critical endpoints for MASH and metabolic dysfunction, including significant HbA1c reduction, improved liver health markers, and favorable lipid profiles, all while maintaining excellent tolerability. The differentiated mechanism of action, improving glucose control independently of weight loss, positions vanoglipel uniquely in a competitive market. Such positive mid-stage clinical data significantly de-risks the asset and suggests a high probability of success in later stages, making it a compelling investment opportunity.

Keywords

MASH, vanoglipel, DA-1241, GPR119 agonist, Phase 2a, clinical trial, metabolic dysfunction-associated steatohepatitis, glucose control, liver health, lipid profiles, biotechnology, cardiometabolic diseases, GLP-1, GIP, PYY, type 2 diabetes, T2D, obesity, DA-1726